Loading...
Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
The risk of hepatitis C virus (HCV) recurrence after direct-acting antiviral (DAA) treatment is <0.5%. However, the distinction between HCV RNA late relapse and reinfection still represents a challenge in virological diagnostics. The aim of this study was to employ next-generation sequencing (NGS...
Na minha lista:
| Udgivet i: | Viruses |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8235384/ https://ncbi.nlm.nih.gov/pubmed/34208646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/v13061151 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|